Recent Investment Analysts’ Ratings Updates for ADARx Pharmaceuticals (ADRX)

ADARx Pharmaceuticals (NASDAQ: ADRX) recently received a number of ratings updates from brokerages and research firms:

• 10/20/2026 – ADARx Pharmaceuticals is now covered by TD Cowen. They set a “buy” rating on the stock.
• 10/20/2026 – ADARx Pharmaceuticals is now covered by UBS Group AG. They set a “buy” rating and a $35.00 price target on the stock.
• 10/20/2026 – ADARx Pharmaceuticals is now covered by Morgan Stanley. They set an “overweight” rating and a $32.00 price target on the stock.
• 10/20/2026 – ADARx Pharmaceuticals was upgraded by UBS Group AG to “strong-buy”.
• 10/20/2026 – ADARx Pharmaceuticals is now covered by JPMorgan Chase & Co.. They set an “overweight” rating and a $38.00 price target on the stock.
• 10/3/2026 – ADARx Pharmaceuticals was upgraded by Wall Street Zen to “hold”.

Insider Transactions at ADARx Pharmaceuticals

In other news, Director Simeon George acquired 1,600,000 shares of the company’s stock in a transaction dated Monday, September 28th. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $27,200,000.00. Following the acquisition, the director directly owned 5,554,094 shares in the company, valued at approximately $94,419,598. This represents a 40.46% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Sr One Capital Management, Llc bought 1,600,000 shares of ADARx Pharmaceuticals stock in a transaction that occurred on Monday, September 28th. The stock was purchased at an average price of $17.00 per share, for a total transaction of $27,200,000.00. Following the acquisition, the insider directly owned 5,554,094 shares of the company’s stock, valued at $94,419,598. The trade was a 40.46% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 3,261,516 shares of company stock worth $55,445,772 in the last ninety days.

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins through RNA-based technologies. The company’s platform is designed to support potent and durable control of protein production, with the goal of creating therapies that may be administered less frequently than conventional treatments.

ADARx is advancing a pipeline of investigational therapeutics for conditions involving the kallikrein-kinin and complement pathways, which are implicated in hereditary angioedema and other immune-mediated or inflammatory diseases.